Latest News and Press Releases

NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON...

Company announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market Zealand will consolidate trading...

Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022 Copenhagen, DK and Boston, MA,...

Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, June 15, 2022 – Zealand Pharma...

Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ:...

COMPANY ANNOUNCEMENT – NO. 27/ 2022 Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to...

Company announcement – No. 26 / 2022 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...

Press release – No. 3/ 2022 Zealand Pharma to Participate in Upcoming Investor Conferences Copenhagen, DK and Boston, MA, U.S. June 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a...

Press Release - No. 2/2022 Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer David Kendall named Zealand Pharma CMOFollows Zealand Pharma’s appointment of...